 Home > Active Ingredient News > Immunology News > AAD 2020: Lebrikizumab treatment for aspecific dermatitis, significant improvement in the quality of life of patients

AAD 2020: Lebrikizumab treatment for aspecific dermatitis, significant improvement in the quality of life of patients

 Last Update: 2020-06-16
 Source: Internet
 Author: User

Tags

cpt2 disease symptoms

society

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lilly and its wholly-owned subsidiary Dermira announced that they will present the latest data on the trial of lebrikizumab's phase IIb clinical trial for moderate to severe aditial dermatitis at the 2020 Virtual Meeting of the American Society of Dermatology (AAD)This study shows that Lebrikizumab can provide rapid and clinically meaningful improvements in patients' itching, sleep and quality of lifeProfessor Clara Kest, Director of the Department of Dermatological Dermatism at The Icahn School of Medicine at Mount Sinai, said: "Understanding the potential of lebrikizumab to improve skin symptoms and other common symptoms in patients with teriotmatitis, such as itching and lack of sleep, is critical to understanding the true potential of lebrikizumabThese results suggest that lebrikizumab can significantly improve the symptoms of the most troubled patients."Aditaphilive dermatitis is a chronic, itchy, inflammatory skin disease that most often affects children, but also affects many adultsClinical features of adhesion dermatitis include dry skin, erythema, oozing and knotting, as well as moss-like changes

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.